Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?
Sign Up to like & getrecommendations! Published in 2020 at "World Journal of Surgical Oncology"
DOI: 10.1186/s12957-020-01932-6
Abstract: Background The Milan criteria (MC) are widely used for the indication of liver transplantation (LTx) in hepatocellular carcinoma (HCC). Good long-term results have also been reported following LTx for patients exceeding the MC. In this… read more here.
Keywords: uts criteria; milan criteria; criteria patients; liver transplantation ... See more keywords
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00739
Abstract: PURPOSE Overexpression of c-Met protein and epidermal growth factor receptor (EGFR) mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has… read more here.
Keywords: lung cancer; non small; met protein; small cell ... See more keywords
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18554
Abstract: SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom… read more here.
Keywords: dose escalation; gastric cancer; cancer; patients met ... See more keywords